AAAAAA
Results:
1-17
|
Results: 17
Authors:
Jelic, S
Babovic, N
Stamatovic, L
Kreacic, M
Matkovic, S
Popov, I
Citation: S. Jelic et al., Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures - A single-center study, MED ONCOL, 18(3), 2001, pp. 189-195
Authors:
Stahel, R
Purkalne, G
Herrstedt, J
Jelic, S
Fervers, B
Kloke, O
Mellstedt, H
Pavlidis, N
Jost, L
Citation: R. Stahel et al., ESMO Minimum Clinical Recommendations - the beginning of a process, ANN ONCOL, 12(8), 2001, pp. 1037-1038
Authors:
Jassem, J
Pienkowski, T
Pluzanska, A
Jelic, S
Gorbunova, V
Mrsic-Krmpotic, Z
Berzins, J
Nagykalnai, T
Wigler, N
Renard, J
Munier, S
Weil, C
Citation: J. Jassem et al., Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial, J CL ONCOL, 19(6), 2001, pp. 1707-1715
Authors:
Popov, I
Jelic, S
Radosavljevic, D
Nikolic-Tomasevic, Z
Citation: I. Popov et al., Amsacrine and cisplatin in poor prognosis patients with metastatic transitional cell carcinoma of the urothelium: A phase-II study, EUR UROL, 40(3), 2001, pp. 324-329
Authors:
Jelic, S
Mitrovic, L
Radosavljevic, D
Elezar, E
Babovic, N
Kovcin, V
Tomasevic, Z
Kovacevic, S
Gavrilovic, D
Radulovic, S
Citation: S. Jelic et al., Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study, LUNG CANC, 34(1), 2001, pp. 1-13
Authors:
Nikolic-Tomasevic, Z
Jelic, S
Popov, I
Radosavljevic, D
Mitrovic, L
Citation: Z. Nikolic-tomasevic et al., Tumor 'flare' hypercalcemia - An additional indication for bisphosphonates?, ONCOL-BASEL, 60(2), 2001, pp. 123-126
Authors:
Konjevic, G
Jovic, V
Radulovic, S
Jelic, S
Dzodic, R
Spuzic, I
Citation: G. Konjevic et al., Therapeutic implications of the kinetics of immunomodulation during singleor combined treatment of melanoma patients with dacarbazine and interferon-alpha, NEOPLASMA, 48(3), 2001, pp. 175-181
Authors:
Nikolic-Tomasevic, Z
Jelic, S
Popov, I
Radosavljevic, D
Citation: Z. Nikolic-tomasevic et al., Irinotecan as second-line treatment in metastatic colorectal cancer: Dilemmas regarding patient selection and toxicity prediction, J CHEMOTHER, 12(3), 2000, pp. 244-251
Authors:
Popov, I
Jelic, S
Radulovic, S
Radosavljevic, D
Nikolic-Tomasevic, Z
Citation: I. Popov et al., Eight-hour infusion versus bolus injection of doxorubicin in the EAP regimen in patients with advanced gastric cancer: A prospective randomised trial, ANN ONCOL, 11(3), 2000, pp. 343-348
Authors:
Colakovic, S
Lukic, V
Mitrovic, L
Jelic, S
Susnjar, S
Marinkovic, J
Citation: S. Colakovic et al., Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer, INT J B MAR, 15(2), 2000, pp. 147-152
Authors:
Babovic, N
Jelic, S
Jovanovic, V
Citation: N. Babovic et al., Primary non-Hodgkin lymphoma of the breast. Is it possible to avoid mastectomy?, J EXP CL C, 19(2), 2000, pp. 149-154
Authors:
Susnjar, S
Vasovic, S
Neskovic-Konstantinovic, Z
Stamatovic, L
Lukic, V
Colakovic, S
Mitrovic, L
Jelic, S
Radulovic, S
Citation: S. Susnjar et al., Mitoxantrone, 5-fluorouracil and low-dose leucovorin in doxorubicin-resistant advanced breast cancer patients: A phase II study, TUMORI, 85(6), 1999, pp. 478-482
Authors:
Jelic, S
Filipovic-Ljeskovic, I
Citation: S. Jelic et I. Filipovic-ljeskovic, Positive serology for Lyme disease Borrelias in primary cutaneous B-cell lymphoma: A study in 22 patients; Is it a fortuitous finding?, HEMATOL ONC, 17(3), 1999, pp. 107-116
Authors:
Milosevic, D
Marinkovic, M
Colovic, M
Jelic, S
Citation: D. Milosevic et al., The absence of correlation between immunoregulatory T cells and induced lymphoproliferative response in treated B-chronic lymphocytic leukemia patients, PANMIN MED, 41(2), 1999, pp. 93-97
Authors:
Jelic, S
Milanovic, N
Tomasevic, Z
Matkovic, S
Gavrilovic, D
Citation: S. Jelic et al., Comparison of two non-anthracycline-containing regimens for elderly patients with diffuse large-cell non Hodgkin's lymphoma - possible pitfalls in results reporting and interpretation, NEOPLASMA, 46(6), 1999, pp. 394-399
Authors:
Popov, I
Jelic, S
Radosavljevic, D
Nikolic-Tomasevic, Z
Citation: I. Popov et al., The role of stable disease in objective response assessment and its impacton survival in advance colorectal cancer: Is "stable disease" a homogenousresponse category?, NEOPLASMA, 46(2), 1999, pp. 132-139
Authors:
Babovic, N
Jelic, S
Milanovic, N
Matkovic, S
Citation: N. Babovic et al., Pilot study of daily ifosfamide 1 g/m(2) until grade III granulocytopenia as second-line chemotherapy for anthracycline-pretreated advanced soft tissue sarcoma, TUMORI, 84(6), 1998, pp. 677-680
Risultati:
1-17
|